Articles
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma
Cancer biomarkers for targeted therapy
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
Epigenetic heterogeneity in cancer
No hay comentarios:
Publicar un comentario